CoronaVirus Interaction Network to Establish Therapies

  • Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Total publications:0 publications

Grant number: 01KI2050B

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $184,743.72
  • Funder

    Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Principal Investigator

    Pending
  • Research Location

    Germany
  • Lead Research Institution

    Justus-Liebig University GieÇ­en
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Viruses rely on interactions with cellular proteins in order to replicate, transmit efficiently and to cause disease. Our knowledge on interactions of coronavirus (CoV) proteins with cellular proteins is still very limited. This is particularly true for the newly emerged SARS-CoV-2, which causes Covid-19. However, such virus-host protein-protein information would not only be highly relevant to understand the biology of CoVs but also to establish intellectually designed therapies. Here we propose to join forces of two laboratories with expertise in CoV biology and viral - host protein interactions to chart the interface between coronaviruses (SARS-CoV-2, SARS-CoV and less pathogenic human CoVs) and the cellular proteome. This network of proteins will be complemented with information druggability of individual proteins in order to identify candidate proteins or drugs, which potentially modulate SARS-CoV-2 spread or pathology. We anticipate that this information will be of critical support for the current endeavour to establish therapies against Covid-19.